

# William G Powderly

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1345002/william-g-powderly-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228  
papers

17,047  
citations

64  
h-index

128  
g-index

244  
ext. papers

18,976  
ext. citations

8.2  
avg, IF

6.17  
L-index

#	Paper	IF	Citations
228	Understanding Drivers of Coronavirus Disease 2019 (COVID-19) Racial Disparities: A Population-Level Analysis of COVID-19 Testing Among Black and White Populations. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2921-e2931	11.6	10
227	Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e3727-e3732	11.6	6
226	Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 1360-1370	2.6	1
225	Long-Term Mortality after Infection in People with HIV. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2021</b> , 7,	5.6	1
224	Association of Adverse Events with Antibiotic Treatment for Urinary Tract Infection. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	3
223	Treatment and mortality outcomes in patients with other extrapulmonary cryptococcal disease compared with central nervous system disease. <i>Mycoses</i> , <b>2021</b> , 64, 174-180	5.2	1
222	A comparison of presentations and outcomes of histoplasmosis across patients with varying immune status. <i>Medical Mycology</i> , <b>2021</b> ,	3.9	6
221	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. <i>Journal of Clinical and Translational Science</i> , <b>2021</b> , 5, e96	0.4	2
220	Clinical predictive models of invasive Candida infection: A systematic literature review. <i>Medical Mycology</i> , <b>2021</b> , 59, 1053-1067	3.9	0
219	Outcomes Associated With Social Distancing Policies in St Louis, Missouri, During the Early Phase of the COVID-19 Pandemic. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2123374	10.4	3
218	COVID-19 and Outpatient Parenteral Antimicrobial Therapy. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 142	8	
217	Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 84, 396-399	3.1	4
216	Infectious disease consultation for candidaemia - AuthorsReply. <i>Lancet Infectious Diseases</i> , <b>2020</b> , 20, 165-166	25.5	0
215	Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease <b>2020</b> ,		17
214	Potential missed opportunities for diagnosis of cryptococcosis and the association with mortality: A cohort study. <i>EClinicalMedicine</i> , <b>2020</b> , 27, 100563	11.3	3
213	Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During Conception and Launch of the Inclusion, Diversity, Access, and Equity Movement Within the IDSA. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, S554-S559	7	2
212	Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. <i>Science Advances</i> , <b>2020</b> , 6,	14.3	117

211	Adopting locally the lessons learned globally: a call to action for academic medical centres in the USA. <i>BMJ Global Health</i> , <b>2020</b> , 5, e002238	6.6	
210	Performance of the Lateral Flow Assay and the Latex Agglutination Serum Cryptococcal Antigen Test in Cryptococcal Disease in Patients with and without HIV. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	3
209	A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus-negative People in the United States. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 252-261	11.6	28
208	Risk factors predicting Candida infective endocarditis in patients with candidemia. <i>Medical Mycology</i> , <b>2020</b> , 58, 593-599	3.9	9
207	Presentation and Mortality of Cryptococcal Infection Varies by Predisposing Illness: A Retrospective Cohort Study. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 977-983.e1	2.4	19
206	Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria. <i>Mycoses</i> , <b>2019</b> , 62, 554-561	5.2	10
205	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 3056-3062	5.1	29
204	Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. <i>Lancet Infectious Diseases</i> , <b>2019</b> , 19, 1336-1344	25.5	37
203	Designing for Accelerated Translation (DART) of Emerging Innovations in Health. <i>Journal of Clinical and Translational Science</i> , <b>2019</b> , 3, 53-58	0.4	15
202	Comfort Discussing HIV Pre-exposure Prophylaxis With Patients Among Physicians in an Urban Emergency Department. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 80, e49-e52	3.1	5
201	Mortality After Cryptococcal Infection in the Modern Antiretroviral Therapy Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, 81-87	3.1	4
200	Brief Report: Aging Attenuates the Association Between Coronary Artery Calcification and Bone Loss Among HIV-Infected Persons. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, 46-50	3.1	
199	Late Presentation and Missed Opportunities for HIV Diagnosis in Guatemala. <i>AIDS and Behavior</i> , <b>2019</b> , 23, 920-928	4.3	5
198	Creation and Assessment of a Clinical Predictive Calculator and Mortality Associated With Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofx253	1	7
197	Sex Venue-Based Network Analysis to Identify HIV Prevention Dissemination Targets for Men Who Have Sex with Men. <i>LGBT Health</i> , <b>2018</b> , 5, 78-85	4.9	4
196	Missed Opportunities to Prescribe HIV Pre-Exposure Prophylaxis by Primary Care Providers in Saint Louis, Missouri. <i>LGBT Health</i> , <b>2018</b> , 5, 250-256	4.9	19
195	Comparative Epidemiology and Outcomes of Human Immunodeficiency virus (HIV), Non-HIV Non-transplant, and Solid Organ Transplant Associated Cryptococcosis: A Population-Based Study. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 608-611	11.6	51
194	Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 379-382	1.6	

193	Understanding mechanisms to promote successful aging in persons living with HIV. <i>International Journal of Infectious Diseases</i> , <b>2018</b> , 66, 56-64	10.5	22
192	376. Predictive Model for Fluconazole Resistance in Patient With Candida Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S146-S146	1	78
191	556. Factors Associated with Integrase Strand Transfer Inhibitor Use Between 2008 and 2015. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S206-S207	1	78
190	394. Outcomes in Patients With Disseminated Noncentral Nervous System Cryptococcus. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S152-S152	1	78
189	395. Missed Opportunities for Diagnosis of Cryptococcal Disease in Patients From Florida. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S152-S152	1	78
188	397. Long-Term Mortality of HIV Patients Following Cryptococcal Infection. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S153-S153	1	78
187	EQUAL Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure Quality of Clinical Cryptococcosis Management. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy299	1	14
186	1030. Risk Predictive Model for Candida Endocarditis in Patients with Candidemia: A 12-year Experience in a Single Tertiary Care Hospital. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S307-S307	1	78
185	Cryptococcal meningitis in AIDS. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2018</b> , 152, 139-150	3	12
184	HIV and its relationship to insulin resistance and lipid abnormalities. <i>Translational Research</i> , <b>2017</b> , 183, 41-56	11	26
183	Cryptococcosis today: It is not all about HIV infection. <i>Current Clinical Microbiology Reports</i> , <b>2017</b> , 4, 88-95.1	3.1	25
182	Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S75-S75	1	78
181	Benefits of Direct-Acting Antivirals for Hepatitis C. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 812-813	8	12
180	Pitfalls Associated With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx242	1	23
179	Proposed U.S. Funding Cuts Threaten Progress on Antimicrobial Resistance. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 738-739	8	4
178	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 1773-1775	11.6	7
177	Comments on cochrane review on direct-acting antivirals for hepatitis C. <i>Hepatology</i> , <b>2017</b> , 66, 1016-1019.1.2	1.2	3
176	Conflicts of Interest Reported in an Abbreviated Time Frame. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1059-1060.1.2	1.2	3

175	Invasive Fungal Infections Secondary to Traumatic Injury. <i>International Journal of Infectious Diseases</i> , <b>2017</b> , 62, 102-111	10.5	30
174	Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients. <i>Journal of Clinical Gastroenterology</i> , <b>2017</b> , 51, 70-76	3	12
173	Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV mono-infection. <i>Aids</i> , <b>2017</b> , 31, 71-79	3.5	15
172	Issues in the Aging HIV-Positive Patient <b>2017</b> , 927-930.e1		
171	Epidemiology of Cryptococcosis and Cryptococcal Meningitis in a Large Retrospective Cohort of Patients After Solid Organ Transplantation. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx004	1	38
170	AIDS-Defining Illnesses at Initial Diagnosis of HIV in a Large Guatemalan Cohort. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx249	1	8
169	Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173057	3.7	20
168	Impact of Infectious Diseases Consultation on Mortality of Cryptococcal infection in Patients without HIV. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 558-564	11.6	35
167	End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofv197	1	37
166	Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia. <i>IDCases</i> , <b>2016</b> , 6, 79-82	2	5
165	Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. <i>BMJ Open</i> , <b>2016</b> , 6, e009586	3	43
164	Recommendations for evaluation and management of bone disease in HIV. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 1242-51	11.6	126
163	Vitamin D and calcium abnormalities in the HIV-infected population. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2014</b> , 43, 743-67	5.5	6
162	Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials. <i>HIV Clinical Trials</i> , <b>2014</b> , 15, 79-86		5
161	Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 508-14	13.4	29
160	Antiretroviral therapy in primary HIV infection. <i>Journal of Comparative Effectiveness Research</i> , <b>2013</b> , 2, 227-9	2.1	
159	Beta-glucan for Pneumocystis pneumonia diagnosis in persons with AIDS: authors' reply. <i>Aids</i> , <b>2013</b> , 27, 2967-8	3.5	1
158	Test performance of blood beta-glucan for <i>Pneumocystis jirovecii</i> pneumonia in patients with AIDS and respiratory symptoms. <i>Aids</i> , <b>2013</b> , 27, 967-972	3.5	31

157	HIV-associated osteoporosis in Ireland: prevalence and risk factors. <i>Future Virology</i> , <b>2012</b> , 7, 791-799	2.4	
156	Human immunodeficiency virus type 1 in Ireland: phylogenetic evidence for risk group-specific subepidemics. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 1073-81	1.6	3
155	Prevalence of hepatitis C virus infection among human immunodeficiency virus-1-infected pregnant women in Malawi: the BAN study. <i>Journal of Clinical Virology</i> , <b>2012</b> , 54, 318-20	14.5	18
154	Candida in HIV infection <b>2012</b> , 359-367		
153	Osteoporosis and bone health in HIV. <i>Current HIV/AIDS Reports</i> , <b>2012</b> , 9, 218-22	5.9	33
152	Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV. <i>Current Opinion in HIV and AIDS</i> , <b>2012</b> , 7, 292-8	4.2	7
151	Documented prevalence of HIV type 1 antiretroviral transmitted drug resistance in Ireland from 2004 to 2008. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 276-81	1.6	6
150	HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo. <i>AIDS Research and Human Retroviruses</i> , <b>2011</b> , 27, 187-99	1.6	40
149	Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 25, 501-15	6.5	41
148	When to start antiretroviral therapy: asking the right question. <i>Future Virology</i> , <b>2011</b> , 6, 401-403	2.4	
147	Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. <i>Aids</i> , <b>2011</b> , 25, 1405-14	3.5	87
146	Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related <i>Pneumocystis jirovecii</i> pneumonia. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 197-202	11.6	92
145	GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. <i>The Open Virology Journal</i> , <b>2011</b> , 5, 109-13	1.9	7
144	Integrase inhibitors in the treatment of HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 2485-8	5.1	45
143	Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. <i>HIV Clinical Trials</i> , <b>2010</b> , 11, 248-59		12
142	A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. <i>HIV Clinical Trials</i> , <b>2010</b> , 11, 80-99		12
141	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 291-322	11.6	1683
140	Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. <i>PLoS ONE</i> , <b>2010</b> , 5, e11416	3.7	113

139	HIV: primary and secondary prophylaxis for opportunistic infections. <i>Clinical Evidence</i> , <b>2010</b> , 2010,		6
138	Opportunistic infections <b>2010</b> , 964-974		1
137	Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. <i>PLoS ONE</i> , <b>2009</b> , 4, e5575	3.7	365
136	Oral fungal infections <b>2009</b> , 501-508		
135	Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. <i>Aids</i> , <b>2009</b> , 23, 1109-18	3.5	188
134	Management of late presentation in HIV: what the data tell us. <i>HIV Therapy</i> , <b>2009</b> , 3, 423-426		
133	Progenitor cell types in HIV-1 infection: bioactivity and emerging targets for treatment. <i>Current HIV Research</i> , <b>2009</b> , 7, 508-18	1.3	2
132	Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. <i>BMC Musculoskeletal Disorders</i> , <b>2008</b> , 9, 33	2.8	32
131	Class-sparing regimens for initial treatment of HIV-1 infection. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2095-106	59.2	575
130	Editorial commentary: dosing amphotericin B in cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 131-2	11.6	7
129	Genetic analysis implicates resistin in HIV lipodystrophy. <i>Aids</i> , <b>2008</b> , 22, 1561-8	3.5	38
128	Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. <i>Aids</i> , <b>2008</b> , 22, 849-56	3.5	24
127	Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. <i>PLoS ONE</i> , <b>2008</b> , 3, e2021	3.7	46
126	Candida in HIV Infection <b>2008</b> , 365-373		
125	HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts. <i>Antiviral Research</i> , <b>2007</b> , 74, 72-6	10.8	15
124	Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2007</b> , 292, E812-9	6	26
123	Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46, 283-90	3.1	95
122	HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 243-50	1.6	50

121	HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 1521-30	1.6	76
120	Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 726-34	11.6	158
119	Cryptococcal infection. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2007</b> , 85, 159-67	3	3
118	Osteopenia and osteoporosis in HIV: pathogenesis and treatment. <i>Current Opinion in HIV and AIDS</i> , <b>2007</b> , 2, 318-23	4.2	9
117	Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. <i>Aids</i> , <b>2006</b> , 20, 2115-6	3.5	19
116	Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. <i>Diabetes</i> , <b>2006</b> , 55, 2849-55	0.9	26
115	APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. <i>Journal of Virology</i> , <b>2006</b> , 80, 2069-72	6.6	60
114	Clinical perspectives of emerging pathogens in bleeding disorders. <i>Lancet, The</i> , <b>2006</b> , 367, 252-61	4.0	48
113	Management of antiretroviral drug toxicity. <i>Current Opinion in HIV and AIDS</i> , <b>2006</b> , 1, 430-6	4.2	
112	A pilot study evaluating time to CD4 T-cell count. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 42, 140-8	3.1	29
111	Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center. <i>Spine</i> , <b>2006</b> , 31, 2695-700	3.3	189
110	Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. <i>Metabolism: Clinical and Experimental</i> , <b>2005</b> , 54, 561-7	12.7	28
109	Hepatic steatosis and HIV infection. <i>AIDS Patient Care and STDs</i> , <b>2005</b> , 19, 356-65	5.8	37
108	Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2005</b> , 38, 426-31	3.1	123
107	Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. <i>Aids</i> , <b>2005</b> , 19, 1439	3.5	8
106	Reducing plasma HIV RNA improves muscle amino acid metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2005</b> , 288, E278-84	6	27
105	Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1045-8	11.6	115
104	A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1473-80	11.6	64



103	Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1326-32	11.6	59
102	Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 419-25	11.6	60
101	Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38 Suppl 2, S109-13	11.6	25
100	Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 180-9	27.4	108
99	The pharmacogenetics of antiretroviral therapy: a review of studies to date. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 98-106	11.6	30
98	Osteoporosis in HIV-infected patients. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , <b>2004</b> , 2, 167-174	2.5	0
97	Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. <i>AIDS Research and Human Retroviruses</i> , <b>2004</b> , 20, 589-94	1.6	42
96	Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 286-91	7	169
95	Has the epidemiology of nosocomial candidemia changed?. <i>Infection Control and Hospital Epidemiology</i> , <b>2004</b> , 25, 628-33	2	66
94	Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. <i>Journal of Clinical Virology</i> , <b>2004</b> , 31, 198-203	14.5	6
93	Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2004</b> , 36, 1011-9	3.1	257
92	The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 206-13	15.9	94
91	Gender-Specific Issues in Fungal Infections <b>2004</b> , 910-922		
90	Limitations of current HIV therapies: opportunities for improvement. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2003</b> , 33 Suppl 1, S7-12; quiz S13, 15-6	3.1	4
89	Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2003</b> , 285, E899-905	6	18
88	Antifungal susceptibility survey of 2,000 bloodstream <i>Candida</i> isolates in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 3149-54	5.9	438
87	A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 37, 634-43	11.6	652
86	Developing a human immunodeficiency virus/acquired immunodeficiency syndrome therapeutic research agenda for resource-limited countries: a consensus statement. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 37, S4-12	11.6	8

85	Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 36, 482-90	11.6	259
84	Opportunities to improve clinical care in HIV disease: designing an effective antiretroviral drug regimen for your patient. Introduction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2003</b> , 33 Suppl 1, S5-6	3.1	
83	A Controlled Phase II Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 279-287	1.6	30
82	Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 851-4	7	49
81	Sorting through confusing messages: the art of HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 31 Suppl 1, S3-9; discussion S24-5	3.1	11
80	Long-term exposure to lifelong therapies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 29 Suppl 1, S28-40	3.1	86
79	Switching effective antiretroviral therapy: a review. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 35, 1219-30	11.6	84
78	Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 1844-7	7	137
77	Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 31, 257-75	3.1	293
76	Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. <i>Annals of Internal Medicine</i> , <b>2002</b> , 137, 105-9	8	240
75	Sex differences in nevirapine rash. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 32, 124-9	11.6	176
74	A prospective study of discontinuing primary and secondary <i>Pneumocystis carinii</i> pneumonia prophylaxis after CD4 cell count increase to > 200 x 10 <sup>6</sup> /l. <i>Aids</i> , <b>2001</b> , 15, 1509-15	3.5	21
73	Treatment of acute cryptococcal disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2001</b> , 2, 1259-68	4	5
72	Elevated lactate levels in hospitalized persons with HIV infection. <i>AIDS Research and Human Retroviruses</i> , <b>2001</b> , 17, 195-201	1.6	14
71	Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. <i>Journal of Applied Physiology</i> , <b>2001</b> , 90, 133-8	3.7	101
70	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. <i>Aids</i> , <b>2001</b> , 15, 591-9	3.5	16
69	AIDS 2001. Clinical treatment. Overview. <i>Aids</i> , <b>2001</b> , 15 Suppl 5, S159-60	3.5	3
68	Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. <i>Aids</i> , <b>2000</b> , 14, 979-85	3.5	67

67	Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. <i>Aids</i> , <b>2000</b> , 14, F63-7	3.5	386
66	Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. <i>Antiviral Research</i> , <b>2000</b> , 45, 47-58	10.8	19
65	Cryptococcal Meningitis in HIV-Infected Patients. <i>Current Infectious Disease Reports</i> , <b>2000</b> , 2, 352-357	3.9	26
64	Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. <i>Aids</i> , <b>2000</b> , 14, 845-52	3.5	24
63	Nelfinavir mesylate. <i>Expert Opinion on Pharmacotherapy</i> , <b>2000</b> , 1, 1429-40	4	22
62	In vivo virulence of <i>Candida albicans</i> isolates causing mucosal infections in people infected with the human immunodeficiency virus. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 182, 955-9	7	29
61	Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. <i>Clinical Infectious Diseases</i> , <b>2000</b> , 30, 749-56	11.6	85
60	Prophylaxis of opportunistic infections. <i>Infectious Disease Clinics of North America</i> , <b>2000</b> , 14, 929-44	6.5	4
59	Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. By Drs Weil and Lenhard. <i>Aids</i> , <b>2000</b> , 14, 2417	3.5	15
58	Insulin resistance in HIV protease inhibitor-associated diabetes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>1999</b> , 21, 209-16	3.1	112
57	Predictors of optimal virological response to potent antiretroviral therapy. <i>Aids</i> , <b>1999</b> , 13, 1873-80	3.5	141
56	Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 1619-23	1.6	34
55	Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 1405-12	1.6	61
54	Immune Reconstitution and the Consequences for Opportunistic Infection Treatment and Prevention. <i>Current Infectious Disease Reports</i> , <b>1999</b> , 1, 99-104	3.9	4
53	Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. <i>Aids</i> , <b>1999</b> , 13, F23-8	3.5	108
52	Pulmonary cryptococcosis in patients without HIV infection. <i>Chest</i> , <b>1999</b> , 115, 734-40	5.3	148
51	Treatment of infection due to <i>Mycobacterium avium</i> complex. <i>Pediatric Infectious Disease Journal</i> , <b>1999</b> , 18, 468-9	3.4	4
50	A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 48-56	7	106

49	Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. <i>Clinical Infectious Diseases</i> , <b>1998</b> , 26, 556-65	11.6	65
48	Recovery of the immune system with antiretroviral therapy: the end of opportunism?. <i>JAMA - Journal of the American Medical Association</i> , <b>1998</b> , 280, 72-7	27.4	158
47	Effect of opportunistic illness on risk of death in HIV disease: abstract and commentary. <i>JAMA - Journal of the American Medical Association</i> , <b>1998</b> , 279, 1500	27.4	1
46	Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1998</b> , 19, 135-44		8
45	A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. <i>Aids</i> , <b>1998</b> , 12, 2439-46	3.5	17
44	Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1998</b> , 275, E577-83	6	30
43	Invasive Fungal Infections: Cryptococcosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>1997</b> , 18, 249-257	3.9	8
42	Molecular epidemiology of mucosal candidiasis in HIV-positive women. <i>AIDS Research and Human Retroviruses</i> , <b>1997</b> , 13, 485-91	1.6	11
41	Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 15-21	59.2	606
40	Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. <i>American Journal of Medicine</i> , <b>1997</b> , 103, 223-32	2.4	124
39	Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. <i>Metabolism: Clinical and Experimental</i> , <b>1997</b> , 46, 303-5	12.7	57
38	Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. <i>Journal of Pain and Symptom Management</i> , <b>1997</b> , 14, 7-14	4.8	162
37	Cryptococcosis. <i>Advances in Pharmacology</i> , <b>1997</b> , 37, 215-51	5.7	13
36	Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1997</b> , 16, 100-7		45
35	Rifabutin induced vitritis in AIDS patients. <i>Ocular Immunology and Inflammation</i> , <b>1996</b> , 4, 219-24	2.8	2
34	Prophylaxis for HIV-related infections: a work in progress. <i>Annals of Internal Medicine</i> , <b>1996</b> , 124, 342-4	8	3
33	Sequence heterogeneity of Nef transcripts in HIV-1-infected subjects at different stages of disease. <i>Virology</i> , <b>1996</b> , 223, 245-50	3.6	12
32	Recent advances in the management of cryptococcal meningitis in patients with AIDS. <i>Clinical Infectious Diseases</i> , <b>1996</b> , 22 Suppl 2, S119-23	11.6	44

31	A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1996</b> , 11, 379-84		31
30	Patterns of opportunistic infections in patients with HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1996</b> , 12, 38-45		32
29	Authors' Reply: <i>Campylobacter</i> spp. Bacteremia in AIDS Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1996</b> , 12, 94		
28	Risks of HIV infection in the health care setting. <i>Annual Review of Medicine</i> , <b>1995</b> , 46, 203-11	17.4	12
27	Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1995</b> , 10, 169-74		38
26	USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. <i>Clinical Infectious Diseases</i> , <b>1995</b> , 21 Suppl 1, S12-31	11.6	54
25	A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 693-9	59.2	290
24	Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , <b>1995</b> , 21 Suppl 1, S103-7	11.6	43
23	A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1534-9	59.2	412
22	Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. <i>American Journal of Medicine</i> , <b>1995</b> , 98, 336-42	2.4	192
21	A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 700-5	59.2	287
20	Resistant Candidiasis. <i>AIDS Patient Care and STDs</i> , <b>1995</b> , 9, 32-36		1
19	Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , <b>1994</b> , 18, 789-92	11.6	142
18	Serious <i>Pseudomonas aeruginosa</i> infections in patients infected with human immunodeficiency virus: a case-control study. <i>Clinical Infectious Diseases</i> , <b>1994</b> , 19, 417-22	11.6	58
17	Resistant candidiasis. <i>AIDS Research and Human Retroviruses</i> , <b>1994</b> , 10, 925-9	1.6	52
16	Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a <i>Cryptococcus neoformans</i> strain from an AIDS patient. <i>FEMS Microbiology Letters</i> , <b>1994</b> , 122, 39-42	2.9	95
15	Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. <i>American Journal of Medicine</i> , <b>1993</b> , 95, 273-8	2.4	38
14	Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. <i>American Journal of Kidney Diseases</i> , <b>1993</b> , 21, 196-201	7.4	22

13	Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. <i>Journal of Infectious Diseases</i> , <b>1993</b> , 168, 463-6	7	68
12	Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. <i>AIDS Research and Human Retroviruses</i> , <b>1993</b> , 9, 1257-63	1.6	14
11	A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1842-8	59.2	313
10	Therapy for cryptococcal meningitis in patients with AIDS. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 14 Suppl 1, S54-9	11.6	67
9	Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. <i>Journal of Infectious Diseases</i> , <b>1992</b> , 165, 548-52	7	66
8	Molecular typing of <i>Candida albicans</i> isolated from oral lesions of HIV-infected individuals. <i>Aids</i> , <b>1992</b> , 6, 81-4	3.5	49
7	A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 845-51	59.2	1014
6	Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 83-9	59.2	545
5	A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 793-8	59.2	304
4	Amphotericin B-resistant yeast infection in severely immunocompromised patients. <i>American Journal of Medicine</i> , <b>1988</b> , 84, 826-32	2.4	200
3	Renal glomerulopathies associated with Hodgkin's disease. <i>Cancer</i> , <b>1985</b> , 56, 874-5	6.4	15
2	Cryptococcus 1128-1133		
1	Cryptococcus 1205-1210		